Literature DB >> 22212685

Lifespan based indirect response models.

Wojciech Krzyzanski1, Juan Jose Perez Ruixo.   

Abstract

In the field of hematology, several mechanism-based pharmacokinetic-pharmacodynamic models have been developed to understand the dynamics of several blood cell populations under different clinical conditions while accounting for the essential underlying principles of pharmacology, physiology and pathology. In general, a population of blood cells is basically controlled by two processes: the cell production and cell loss. The assumption that each cell exits the population when its lifespan expires implies that the cell loss rate is equal to the cell production rate delayed by the lifespan and justifies the use of delayed differential equations for compartmental modeling. This review is focused on lifespan models based on delayed differential equations and presents the structure and properties of the basic lifespan indirect response (LIDR) models for drugs affecting cell production or cell lifespan distribution. The LIDR models for drugs affecting the precursor cell production or decreasing the precursor cell population are also presented and their properties are discussed. The interpretation of transit compartment models as LIDR models is reviewed as the basis for introducing a new LIDR for drugs affecting the cell lifespan distribution. Finally, the applications and limitations of the LIDR models are discussed.

Entities:  

Mesh:

Year:  2012        PMID: 22212685      PMCID: PMC3684441          DOI: 10.1007/s10928-011-9236-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  50 in total

1.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Authors:  L A Harker; L K Roskos; U M Marzec; R A Carter; J K Cherry; B Sundell; E N Cheung; D Terry; W Sheridan
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 3.  Pharmacodynamic modeling of time-dependent transduction systems.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2001-09       Impact factor: 6.875

4.  A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats.

Authors:  Itay Perlstein; David Stepensky; Wojciech Krzyzanski; Amnon Hoffman
Journal:  J Pharm Sci       Date:  2002-12       Impact factor: 3.534

5.  Solving delay differential equations in S-ADAPT by method of steps.

Authors:  Robert J Bauer; Gary Mo; Wojciech Krzyzanski
Journal:  Comput Methods Programs Biomed       Date:  2013-06-27       Impact factor: 5.428

6.  Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.

Authors:  G J Fetterly; J M Tamburlin; R M Straubinger
Journal:  Biopharm Drug Dispos       Date:  2001-09       Impact factor: 1.627

7.  D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

Authors:  Leonid A Khinkis; Wojciech Krzyzanski; William J Jusko; William R Greco
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

8.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

9.  Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.

Authors:  Elena Soto; Alexander Staab; Christiane Doege; Matthias Freiwald; Gerd Munzert; Iñaki F Trocóniz
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-24       Impact factor: 3.333

Review 10.  Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

Authors:  Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

View more
  9 in total

1.  General relationship between transit compartments and lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-23       Impact factor: 2.745

2.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

3.  Delayed logistic indirect response models: realization of oscillating behavior.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-08       Impact factor: 2.745

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.

Authors:  David Ternant; Theodora Bejan-Angoulvant; Christophe Passot; Denis Mulleman; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

5.  Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.

Authors:  Wojciech Krzyzanski; Liviawati Sutjandra; Juan Jose Perez-Ruixo; Bethlyn Sloey; Andrew T Chow; Yow-Ming Wang
Journal:  Pharm Res       Date:  2012-12-19       Impact factor: 4.200

6.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

7.  Romiplostim dose-response in patients with myelodysplastic syndromes.

Authors:  Juan Jose Perez Ruixo; Sameer Doshi; Yow-Ming C Wang; Diane R Mould
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

8.  Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.

Authors:  Gary Mo; Frank Gibbons; Patricia Schroeder; Wojciech Krzyzanski
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

9.  A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Authors:  M Wilbaux; M Tod; J De Bono; D Lorente; J Mateo; G Freyer; B You; E Hénin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.